Dasatinib and Risperidone Injection (IM)
Determining the interaction of Dasatinib and Risperidone Injection (IM) and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Using dasatinib together with risperiDONE can increase the risk of an irregular heart rhythm that may be serious and potentially life-threatening, although it is a relatively rare side effect. You may be more susceptible if you have a heart condition called congenital long QT syndrome, other cardiac diseases, conduction abnormalities, or electrolyte disturbances (for example, magnesium or potassium loss due to severe or prolonged diarrhea or vomiting). Talk to your doctor if you have any questions or concerns. You should seek immediate medical attention if you develop sudden dizziness, lightheadedness, fainting, shortness of breath, or heart palpitations during treatment with these medications, whether together or alone. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:MONITOR: In vitro data suggest that dasatinib has the potential to prolong QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In single-arm clinical studies involving patients with leukemia treated with dasatinib, the mean QTc interval changes from baseline using Fridericia's method (QTcF) were 3 to 6 msec; the upper 95% confidence intervals for all mean changes from baseline were less than 8 msec. Nine patients had QTc prolongation reported as an adverse event, three of whom (less than 1%) experienced a QTcF greater than 500 msec. In general, the risk of an individual agent or a combination of agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances (e.g., hypokalemia, hypomagnesemia). In addition, the extent of drug-induced QT prolongation is dependent on the particular drug(s) involved and dosage(s) of the drug(s).
MANAGEMENT: Caution is recommended if dasatinib is used in combination with cumulative high-dose anthracycline therapy or other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.
- "Product Information. Sprycel (dasatinib)." Bristol-Myers Squibb, Princeton, NJ.
Generic Name: risperidone
Brand name: Risperdal, Perseris, Risperdal Consta, Risperdal Consta, Risperdal M-Tab
Synonyms: Risperidone, RisperiDONE
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Dasatinib-Risperidone Injection (Subcutaneous)
- Dasatinib-Risperidone Intramuscular
- Dasatinib-RisperiDONE M-Tab
- Dasatinib-Risperidone Oral Solution
- Dasatinib-Risperidone Orally Disintegrating
- Dasatinib-Risperidone Orally Disintegrating Tablets
- Risperidone Injection (IM)-Dasetta 1/35
- Risperidone Injection (IM)-Dasetta 7/7/7
- Risperidone Injection (IM)-DaTscan
- Risperidone Injection (IM)-Daunorubicin
- Risperidone Injection (IM)-Daunorubicin (Conventional)
- Risperidone Injection (IM)-Daunorubicin (Liposomal)